On the stock market since 1994, it operates in the world of health and science. It has 2,700 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
No real growth (3% a year). Red columns mark years that ended in a loss.
The gap is $57.9M. In times of high interest rates, a gap like that can squeeze a company.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It pays out $0.22 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 6% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, DVCR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DVCR is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.